Abstract

ObjectivesTo explore which preoperative clinical data and conventional MRI findings may indicate microvascular invasion (MVI) of combined hepatocellular-cholangiocarcinoma (cHCC-CCA) and have clinical significance.MethodsThe study enrolled 113 patients with histopathologically confirmed cHCC-CCA (MVI-positive group [n = 56], MVI-negative group [n = 57]). Two radiologists retrospectively assessed the preoperative MRI features (qualitative analysis of morphology and dynamic enhancement features), and each lesion was assigned according to the LI-RADS. Preoperative clinical data were also evaluated. Logistic regression analyses were used to assess the relative value of these parameters as potential predictors of MVI. Recurrence-free survival (RFS) rates after hepatectomy in the two groups were estimated using Kaplan–Meier survival curves and compared using the log-rank test.ResultsThe majority of cHCC-CCAs were categorized as LR-M. On multivariate analysis, a higher serum AFP level (OR, 0.523; 95% CI, 0.282–0.971; p = 0.040), intratumoral fat deposition (OR, 14.368; 95% CI, 2.749–75.098; p = 0.002), and irregular arterial peritumoral enhancement (OR, 0.322; 95% CI, 0.164–0.631; p = 0.001) were independent variables associated with the MVI of cHCC-CCA. After hepatectomy, patients with MVI of cHCC-CCA showed earlier recurrence than those without MVI (hazard ratio [HR], 0.402; 95% CI, 0.189–0.854, p = 0.013).ConclusionA higher serum AFP level and irregular arterial peritumoral enhancement are potential predictive biomarkers for the MVI of cHCC-CCA, while intratumoral fat detected on MRI suggests a low risk of MVI. Furthermore, cHCC-CCAs with MVI may have worse surgical outcomes with regard to early recurrence than those without MVI.Key Points• Higher serum levels of AFP combined with irregular arterial peritumoral enhancement are independent risk factors for the MVI of cHCC-CCA, while fat deposition might be a protective factor.• cHCC-CCA with MVI may have a higher risk of early recurrence after surgery.• Most cHCC-CCAs were categorized as LR-M in this study, and no significant difference was found in MVI based on LI-RADS category.

Highlights

  • Combined hepatocellular-cholangiocarcinoma is a relatively uncommon subtype of primary hepatic malignant tumors, accounting for 2–5% of primary liver carcinomas (PLCs) [1,2,3]

  • Most cHCC-CCAs were categorized as LR-M in this study, and no significant difference was found in microvascular invasion (MVI) based on Liver Imaging Reporting and Data System (LI-RADS)

  • Our results illustrated that a higher serum level of AFP and irregular arterial phase peritumoral enhancement may indicate a higher risk of the MVI of cHCC-CCA, while intratumoral fat detected on magnetic resonance imaging (MRI) suggests a lower risk

Read more

Summary

Introduction

Combined hepatocellular-cholangiocarcinoma (cHCC-CCA) is a relatively uncommon subtype of primary hepatic malignant tumors, accounting for 2–5% of primary liver carcinomas (PLCs) [1,2,3]. The risk factors identified as being related to prognosis of cHCC-CCA are not uniform across studies because of the relatively low incidence and variations in sample size. Studies have shown that the level of cancer antigen 19-9 (CA19-9) or the presence of cirrhosis is a factor affecting the prognosis of cHCC-CCA [9, 10]. Previous studies have confirmed that microvascular invasion (MVI) is a prognostic factor for tumor recurrence and is associated with poor survival outcomes in HCC [11,12,13,14] and ICC [15, 16], the relationship between prognosis and the presence of MVI in cHCC-CCA patients has not yet been established

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call